Company Encyclopedia
View More
name
DSL
603233.SH
DaShenLin Pharmaceutical Group Co., Ltd. manufactures, distributes, and retails pharmaceutical products in China. It provides Chinese and Western patent medicines, ginseng and antler tonic medicinal materials, Chinese herbal medicine slices, health products, medical devices, and other commodities. The company was incorporated in 1999 and is based in Guangzhou, China.
90.72 B
603233.SHMarket value -Rank by Market Cap -/-

Financial Score

06/12/2025 Update
C
Drug RetailIndustry
Industry Ranking4/9
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreB
    • ROE16.14%A
    • Profit Margin4.24%C
    • Gross Margin34.65%C
  • Growth ScoreC
    • Revenue YoY1.11%C
    • Net Profit YoY33.80%B
    • Total Assets YoY0.78%C
    • Net Assets YoY4.50%C
  • Cash ScoreB
    • Cash Flow Margin2358.75%A
    • OCF YoY1.11%C
  • Operating ScoreA
    • Turnover1.03A
  • Debt ScoreD
    • Gearing Ratio67.45%D

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    CITIC Construction Investment: The pharmacy industry is currently recovering moderately, and transformation is expected to catalyze valuation enhancement

    CITIC Construction Investment released a research report indicating that the pharmacy industry is experiencing a mild recovery, while traditional pharmacies face development pain points, making differentiated transformation imperative. The industry needs to adapt to the economic environment, policy changes, and consumer habits, differentiating into specialized and diversified pharmacies. Specialized pharmacies meet the needs of patients discharged from hospitals, while diversified pharmacies focus on daily health needs. Compared to Japan, pharmacy companies need to leverage policy support to promote differentiated development in order to gain additional growth

    Zhitong·
    SH
    605266
    +0.40%
    SZ
    002727
    +0.31%
    SH
    603233
    -0.50%
    Zhitong·
    SH
    605266
    +0.40%
    SZ
    002727
    +0.31%
    SH
    603233
    -0.50%

    Bank of China International: The Medical Insurance Bureau clarifies that centralized procurement is against involution, focusing on re-evaluation opportunities in the pharmaceutical sector

    Bank of China International released a research report stating that the Medical Insurance Bureau has launched the 11th batch of centralized procurement, emphasizing the principles of "stabilizing clinical practices, ensuring quality, preventing collusion, and resisting involution," while optimizing procurement rules. This centralized procurement will no longer simply reference the lowest price; companies with the lowest bids are required to publicly explain the rationale and commit to not quoting below cost. It is expected that as price expectations stabilize, the profitability of the pharmaceutical industry will gradually improve, and it is recommended to pay attention to the revaluation opportunities in the pharmaceutical sector

    Zhitong·
    SH
    603233
    -0.50%
    SH
    688621
    -1.60%
    SH
    600993
    +0.53%
    Zhitong·
    SH
    603233
    -0.50%
    SH
    688621
    -1.60%
    SH
    600993
    +0.53%

    China Post Securities: The retail pharmacy industry continues to clear out, and the ongoing coordination is expected to bring performance growth

    China Post Securities released a research report indicating that the retail pharmacy industry is accelerating its clearance, with the number of closed pharmacies reaching 39,228 in 2024. It is expected that after industry consolidation, leading pharmacies will see a recovery in customer traffic. Leading pharmacies, leveraging their first-mover advantage in outpatient management, will attract more customers, enhance medical insurance consumption and related product consumption, thereby increasing the average transaction value and performance. Policy-driven prescription outflow and the trend of incorporating retail pharmacies into medical insurance management will further promote industry development

    Zhitong·
    SH
    603233
    -0.50%
    SH
    605266
    +0.40%
    SZ
    002727
    +0.31%
    Zhitong·
    SH
    603233
    -0.50%
    SH
    605266
    +0.40%
    SZ
    002727
    +0.31%

    DSL shareholder Ke Jinlong plans to reduce his holdings by no more than 2%

    According to the Zhitong Finance APP, DSL announced that in order to adjust its asset and financing structure, repay personal debts, and reduce the stock pledge ratio, shareholder Ke Jinlong intends to reduce his holdings of the company's shares by no more than 22.777 million shares through block trading, which is no more than 2% of the company's total share capital

    Zhitong·
    SH
    603233
    -0.50%
    Zhitong·
    SH
    603233
    -0.50%

    WanLian Security: Initiates "Buy" rating for DSL, a leading large chain pharmacy enterprise in China

    WanLian Security's research report points out that DSL is a leading large chain pharmacy enterprise in the South China region and ranks among the top in the country. Retail from directly-operated stores is the main source of the company's revenue and profit. In recent years, the company has completed its layout in 21 provinces through "self-built + mergers and acquisitions + franchising." In the future, the company will focus on developing existing stores, with significant room for improvement in profitability and operational efficiency of stores outside the province, driving the company's market share increase in various provinces and cities. The initial coverage gives a "Buy" rating

    Zhitong·
    SH
    603233
    -0.50%
    Zhitong·
    SH
    603233
    -0.50%
    © 2025 Longbridge｜Disclaimer